8. Sáez LR, Álvarez DF, Martínez IP et al. Refractory iron-deficiency anemia and gluten intolerance—Response to gluten-free diet. Rev Esp Enferm Dig 2011 Jul; 103(7):349–54.
9. Sandstead HH. Human zinc deficiency: discovery to initial translation. Adv Nutr 2013 Jan 1; 4(1):76–81.
10. Holm PB et al. J Nutr 2002 Mar; 132(3):514S–6S.
11. Prasad AS. Discovery of human zinc deficiency: its impact on human health and disease. Adv Nutr 2013 Mar 1; 4(2):176–90.
12. Gibson RS. A historical review of progress in the assessment of dietary zinc intake as an indicator of population zinc status. Adv Nutr 2012(3):772–82.
13. Bohn T, Davidsson L, Walczyk T, Hurrell RF. Phytic acid added to white-wheat bread inhibits fractional apparent magnesium absorption in humans. Am J Clin Nutr 2004 Mar; 79(3):418–23.
14. Jenkins DJ, Kendall CW, Vidgen E, Augustin LS, Parker T, Faulkner D et al. Effect of high vegetable protein diets on urinary calcium loss in middle-aged men and women. Eur J Clin Nutr 2003 Feb; 57(2):376-82.
15. Hollon J, Puppa EL, Greenwald B et al. Effect of gliadin on permeability of intestinal biopsy explants from celiac disease patients and patients with non-celiac gluten sensitivity. Nutrients 2015 Feb 27; 7(3):1565–76.
16. Anderson OD, Dong L, Huo N, Gu YQ. A new class of wheat gliadin genes and proteins. PLoS One 2012; 7(12):e52139.
17. Sandhu JS, Fraser DR. Effect of dietary cereals on intestinal permeability in experimental enteropathy in rats. Gut 1983 Sep; 24(9):825–30.
18. Fasano A. Zonulin, regulation of tight junctions, and autoimmune diseases. Ann NY Acad Sci 2012 Jul; 1258(1):25–33.
19. Lo Iacono O, Petta S, Venezia G et al. Anti-tissue transglutaminase antibodies in patients with abnormal liver tests: Is it always coeliac disease? Am J Gastroenterol 2005 Nov; 100(11):2472–7.
20. Tatham AS, Shewry PR. Allergens in wheat and related cereals. Clin Exp Allergy 2008; 38(11):1712–26.
21. Bourne C, Charpiat B, Charhon N et al. [Emergent adverse effects of proton pump inhibitors]. Presse Med 2013 Feb; 42(2):e53–62.
22. Tieyjeh IM, Abdulhak AB, Riaz M et al. The association between histamine 2 receptor antagonist use and Clostridium difficile infection: a systematic review and meta-analysis. PLoS One 2013; 8(3):e56498.
23. Biswas S, Benedict SH, Lynch SG, LeVine SM. Potential immunological consequences of pharmacological suppression of gastric acid production in patients with multiple sclerosis. BMC Med 2012 Jun 7; 10:57.
24. Vazquez-Roque MI, Camilleri M, Smirt T et al. A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function. Gastroenterol 2013 May; 144 (5):903–11.
25. Ding XW, Liu YX, Fang XC et al. The relationships between small intestinal bacterial overgrowth and irritable bowel syndrome. Eur Rev Med Pharmacol Sci 2017 Nov; 21(22):5191–6.
26. Ebert C, Nebe B, Walzel H, Weber H, Jonas L. Inhibitory effect of the lectin wheat germ agglutinin (WGA) on the proliferation of AR42J cells. Acta Histochem 2009; 111(4):335–42.
27. Santer R, Leung YK, Alliet P et al. The role of carbohydrate moieties of cholecystokinin receptors in cholecystokinin octapeptide binding: alteration of binding data by specific lectins. Biochim Biophys Acta 1990 Jan 23; 1051(1):78–83.
28. Sonnenberg A, Müller AD. Constipation and cathartics as risk factors of colorectal cancer: a meta-analysis. Pharmacology 1993 Oct; 47 (Suppl 1):224–33.
29. Catassi C, Bai JC, Bonaz B et al. Non-celiac gluten sensitivity: the new frontier of gluten related disorders. Nutrients 2013 Sep 26 [Epub ahead of print].
30. Volta U, Tovoli F, Cicola R et al. Serological tests in gluten sensitivity (nonceliac gluten intolerance). J Clin Gastroenterol 2012 Sep; 46(8):680–5.
31. Brown K, DeCoffe D, Molcan E, Gibson DL. Diet-induced dysbiosis of the intestinal microbiota and the effects on immunity and disease. Nutrients 2012 Aug; 4(8):1095–119.
32. Sachdev AH, Pimentel M. Gastrointestinal bacterial overgrowth: pathogenesis and clinical significance. Ther Adv Chronic Dis 2013 Sep; 4(5):223–31.
33. Khoshini R, Dai SC, Lezcano S, Pimentel M. A systematic review of diagnostic tests for small intestinal bacterial overgrowth. Dig Dis Sci 2008 Jun; 53(6):1443–54.
34. Walker AW, Ince J, Duncan SH et al. Dominant and diet-responsive groups of bacteria within the human colonic microbiota. ISME J 2011 Feb; 5(2):220–30.
35. Wu GD, Chen J, Hoffmann C et al. Linking long-term dietary patterns with gut microbial enterotypes. Science 2011 Oct 7; 334(6052):105–8.
CHAPTER 8
1. Zhao X. 434-PP. Presented at the American Diabetes Association 70th Scientific Sessions; June 25, 2010.
2. Franco OH, Steyerberg EW, Hu FB et al. Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease. Arch Intern Med 2007 Jun 11; 167(11):1145–51.
3. Daniel M, Rowley KG, McDermott R et al. Diabetes incidence in an Australian aboriginal population: an 8-year follow-up study. Diabetes Care 1999; 22:1993–8.
4. Ebbesson SO, Schraer CD, Risica PM et al. Diabetes and impaired glucose tolerance in three Alaskan Eskimo populations: the Alaska-Siberia Project. Diabetes Care 1998; 21:563–9.
5. Cordain L. Cereal grains: humanity’s double-edged sword. In Simopoulous AP, ed., Evolutionary aspects of nutrition and health. World Rev Nutr Diet 1999; 84:19–73.
6. Reaven GM. Banting Lecture 1988: role of insulin resistance in human disease. Diabetes 1988; 37:1595–607.
7. Crawford EM. Death rates from diabetes mellitus in Ireland 1833–1983: a historical commentary. Ulster Med J 1987 Oct; 56(2):109–15.
8. Centers for Disease Control. New CDC report: more than 100 million Americans have diabetes or prediabetes, at https://www.cdc.gov/media/releases/2017/p0718-diabetes-report.html.
9. Ibid.
10. Ginsberg HN, MacCallum PR. The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus. J Cardiometab Syndr 2009 Spring; 4(2):113–9.
11. Centers for Disease Control. Prevalence of Obesity Among Adults and Youth: United States, 2011–2014, at https://www.cdc.gov/nchs/data/databriefs/db219.pdf.
12. Wang Y, Beydoun MA, Liang L et al. Will all Americans become overweight or obese? Estimating the progression and cost of the US obesity epidemic. Obesity (Silver Spring) 2008 Oct; 16(10):2323–30.
13. USDA. U.S. Per capita wheat use, at https://www.ers.usda.gov/topics/crops/wheat/wheat-sector-at-a-glance/.
14. Macor C, Ruggeri A, Mazzonetto P et al. Visceral adipose tissue impairs insulin secretion and insulin sensitivity but not energy expenditure in obesity. Metabolism 1997 Feb; 46(2):123–9.
15. Marchetti P, Lupi R, Del Guerra S et al. The beta-cell in human type 2 diabetes. Adv Exp Med Biol 2010; 654:501–14.
16. Ibid.
17. Wajchenberg BL. Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007 Apr; 28(2):187–218.
18. Banting FG, Best CH, Collip JB et al. Pancreatic extracts in the treatment of diabetes mellitus: preliminary report. Can Med Assoc J 1922 March; 12(3): 141–6.
19. Westman EC, Vernon MC. Has carbohydrate-restriction been forgotten as a treatment for diabetes mellitus? A perspective on the ACCORD study design. Nutr Metab (Lond) 2008; 5:10.
20. Volek JS, Sharman M, Gómez A et al. Comparison of energy-restricted very low-carbohydrate and low-fat diets on weight loss and body composition in overweight men and women. Nutr Metab (Lond) 2004 Nov 8; 1(1):13.
21. Volek JS, Phinney SD, Forsythe CE et al. Carbohydrate restriction has a more favorable impact on the metabolic syndrome than a low fat diet. Lipids 2009 Apr; 44(4):297–309.
22
. Westman EC, Yancy WS, Mavropoulos JC et al. The effect of a low-carbohydrate, ketogenic diet versus a low-glycemic index diet on glycemic control in type 2 diabetes mellitus. Nutr Metab (Lond) 2008 Dec 19; 5:36.
23. Saslow LR, Mason AE, Kim S et al. An online intervention comparing a very low-carbohydrate ketogenic diet and lifestyle recommendations versus a plate method diet in overweight individuals with type 2 diabetes: a randomized controlled trial. J Med Internet Res 2017 Feb 13; 19(2):e36.
24. Stern L, Iqbal N, Seshadri P et al. The effects of a low-carbohydrate versus conventional weight loss diets in severely obese adults: one-year follow-up of a randomized trial. Ann Intern Med 2004; 140:778–85.
25. Samaha FF, Iqbal N, Seshadri P et al. A low-carbohydrate as compared with a low-fat diet in severe obesity. N Engl J Med 2003; 348:2074–81.
26. Gannon MC, Nuttall FQ. Effect of a high-protein, low-carbohydrate diet on blood glucose control in people with type 2 diabetes. Diabetes 2004; 53:2375–82.
27. In one study, carbohydrates were reduced to 30 grams per day; 11.2 pounds of weight loss on average resulted and HbA1c dropped from 7.4 to 6.6 percent over a year.
28. Boden G, Sargrad K, Homko C et al. Effect of a low-carbohydrate diet on appetite, blood glucose levels and insulin resistance in obese patients with type 2 diabetes. Ann Intern Med 2005; 142:403–11.
29. Meng Y, Bai H, Wang S et al. Efficacy of low carbohydrate diet for type 2 diabetes mellitus management: a systematic review and meta-analysis of randomized controlled trials. Diabetes Res Clin Pract 2017 Sep; 131:124–31.
30. Ventura A, Neri E, Ughi C et al. Gluten-dependent diabetes-related and thyroid related autoantibodies in patients with celiac disease. J Pediatr 2000; 137:263–5.
31. Vehik K, Hamman RF, Lezotte D et al. Increasing incidence of type 1 diabetes in 0- to 17-year-old Colorado youth. Diabetes Care 2007 Mar; 30(3):503–9.
32. DIAMOND Project Group. Incidence and trends of childhood type 1 diabetes worldwide 1990–1999. Diabet Med 2006 Aug; 23(8):857–66.
33. Hansen D, Bennedbaek FN, Hansen LK et al. High prevalence of coeliac disease in Danish children with type 1 diabetes mellitus. Acta Paediatr 2001 Nov; 90(11):1238–43.
34. Barera G, Bonfanti R, Viscardi M et al. Occurrence of celiac disease after onset of type 1 diabetes: A 6-year prospective longitudinal study. Pediatrics 2002 May; 109(5):833–8.
35. Ibid.
36. Funda DP, Kaas A, Bock T et al. Gluten-free diet prevents diabetes in NOD mice. Diabetes Metab Res Rev 1999; 15:323–7.
37. Maurano F, Mazzarella G, Luongo D et al. Small intestinal enteropathy in non-obese diabetic mice fed a diet containing wheat. Diabetologia 2005 May; 48(5):931–7.
CHAPTER 9
1. Bengmark S. Advanced glycation and lipoxidation end products—amplifiers of inflammation: the role of food. J Parent Enter Nutr 2007 Sep–Oct; 31(5):430–40.
2. Uribarri J, Cai W, Peppa M et al. Circulating glycotoxins and dietary advanced glycation endproducts: two links to inflammatory response, oxidative stress, and aging. J Gerontol 2007 Apr; 62A:427–33.
3. Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care 1999 Jan; 22(1):99–111.
4. Kilhovd BK, Giardino I, Torjesen PA et al. Increased serum levels of the specific AGE-compound methylglyoxal-derived hydroimidazolone in patients with type 2 diabetes. Metabolism 1003; 52:163–7.
5. Monnier VM, Battista O, Kenny D et al. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial. Diabetes 1999; 48:870–80.
6. Goh S, Cooper ME. The role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab 2008; 93:1143–52.
7. Uribarri J, Tuttle KR. Advanced glycation end products and nephrotoxicity of high-protein diets. Clin J Am Soc Nephrol 2006; 1:1293–9.
8. Bucala R, Makita Z, Vega G et al. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA 1994; 91:9441–5.
9. Stitt AW, He C, Friedman S et al. Elevated AGE-modified Apo B in sera of euglycemic, normolipidemic patients with atherosclerosis: relationship to tissue AGEs. Mol Med 1997; 3:617–27.
10. Moreira PI, Smith MA, Zhu X et al. Oxidative stress and neurodegeneration. Ann NY Acad Sci 2005; 1043:543–52.
11. Nicolls MR. The clinical and biological relationship between type 2 diabetes mellitus and Alzheimer’s disease. Curr Alzheimer Res 2004; 1:47–54.
12. Bengmark. J Parent Enter Nutr 2007 Sep–Oct; 31(5):430–40.
13. Seftel AD, Vaziri ND, Ni Z et al. Advanced glycation end products in human penis: elevation in diabetic tissue, site of deposition, and possible effect through iNOS or eNOS. Urology 1997; 50:1016–26.
14. Stitt AW. Advanced glycation: an important pathological event in diabetic and age related ocular disease. Br J Ophthalmol 2001; 85:746–53.
15. Uribarri. J Gerontol 2007 Apr; 62A:427–33.
16. Vlassara H, Cai W, Crandall J et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk for complications of diabetic angiopathy. Proc Natl Acad Sci USA 2002; 99:15596–601.
17. Negrean M, Stirban A, Stratmann B et al. Effects of low- and high-advanced glycation endproduct meals on macro- and microvascular endothelial function and oxidative stress in patients with type 2 diabetes mellitus. Am J Clin Nutr 2007; 85:1236–43.
18. Goh et al. J Clin Endocrinol Metab 2008; 93:1143–52.
19. Centers for Disease Control. New CDC report: more than 100 million Americans have diabetes or prediabetes, at https://www.cdc.gov/media/releases/2017/p0718-diabetes-report.html.
20. Sakai M, Oimomi M, Kasuga M. Experimental studies on the role of fructose in the development of diabetic complications. Kobe J Med Sci 2002; 48(5):125–36.
21. Goldberg T, Cai W, Peppa M et al. Advanced glycoxidation end products in commonly consumed foods. J Am Diet Assoc 2004; 104:1287–91.
22. Negrean et al. Am J Clin Nutr 2007; 85:1236–43.
23. Sarwar N, Aspelund T, Eiriksdottir G et al. Markers of dysglycaemia and risk of coronary heart disease in people without diabetes: Reykjavik prospective study and systematic review. PLoS Med 2010 May 25; 7(5):e1000278.
24. International Expert Committee. International Expert Committee report on the role of the HbA1c assay in the diagnosis of diabetes. Diabetes Care 2009; 32:1327–44.
25. Khaw KT, Wareham N, Luben R et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). Brit Med J 2001 Jan 6; 322(7277):15–8.
26. Gerstein HC, Swedberg K, Carlsson J et al. The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: assessment of Reduction in Mortality and Morbidity (CHARM) program. Arch Intern Med 2008 Aug 11; 168(15):1699–704.
27. Khaw et al. Brit Med J 2001 Jan 6; 322(7277):15–8.
28. Swami-Mruthinti S, Shaw SM, Zhao HR et al. Evidence of a glycemic threshold for the development of cataracts in diabetic rats. Curr Eye Res 1999 Jun; 18(6):423–9.
29. Rowe NG, Mitchell PG, Cumming RG, Wans JJ. Diabetes, fasting blood glucose and age-related cataract: the Blue Mountains Eye Study. Opththalmic Epidemiol 2000 Jun; 7(2):103–14.
30. Sperduto RD, Seigel D. Senile lens and senile macular changes in a population-based sample. Am J Opththalmol 1980 Jul; 90(1):86�
��91.
31. Stitt et al. Mol Med 1997; 3:617–27.
32. Ishibashi T, Kawaguchi M, Sugimoto K et al. Advanced glycation end product–mediated matrix metallo-proteinase-9 and apoptosis via renin-angiotensin system in type 2 diabetes. J Atheroscler Thromb 2010 Jun 30; 17(6):578–89.
33. Vlassara H, Torreggiani M, Post JB et al. Role of oxidants/inflammation in declining renal function in chronic kidney disease and normal aging. Kidney Int Suppl 2009 Dec; (114):S3–11.
CHAPTER 10
1. Stalenhoef AF, de Graaf J. Association of fasting and nonfasting serum triglycerides with cardiovascular disease and the role of remnant-like lipoproteins and small dense LDL. Curr Opin Lipidol 2008; 19:355–61.
2. Lamarche B, Lemieux I, Després JP. The small, dense LDL phenotype and the risk of coronary heart disease: epidemiology, patho-physiology and therapeutic aspects. Diabetes Metab 1999 Sep; 25(3):199–211.
3. Packard CJ. Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein. Biochem Soc Trans 2003; 31:1066–9.
4. De Graaf J, Hak-Lemmers HL, Hectors MP et al. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler Thromb 1991 Mar–Apr; 11(2):298–306.
5. Younis N, Sharma R, Soran H et al. Glycation as an atherogenic modification of LDL. Curr Opin Lipidol 2008 Aug; 19(4):378–84.
6. Zambon A, Hokanson JE, Brown BG, Brunzell JD. Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density. Circulation 1999 Apr 20; 99(15):1959–64.
7. Ginsberg HN. New perspectives on atherogenesis: role of abnormal triglyceride-rich lipoprotein metabolism. Circulation 2002; 106:2137–42.
8. Stalenhoef et al. Curr Opin Lipidol 2008; 19:355–61.
9. Ford ES, Li C, Zhgao G et al. Hypertriglyceridemia and its pharmacologic treatment among US adults. Arch Intern Med 2009 Mar 23; 169(6):572–8.
10. Superko HR. Beyond LDL cholesterol reduction. Circulation 1996 Nov 15; 94(10):2351–4.
Wheat Belly (Revised and Expanded Edition) Page 41
